![Rachel Maers](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Rachel Maers first degree
Entity | Entity type | Industry | |
---|---|---|---|
Innoskel SASU
![]() Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies.
4
| Holding Company | Biotechnology | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Rachel Maers via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Université Catholique de Louvain | College/University | Doctorate Degree | |
Locanabio, Inc.
![]() Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | Packaged Software | Director/Board Member | |
University of Surrey | College/University | Undergraduate Degree | |
Dymedex Consulting LLC
![]() Dymedex Consulting LLC Miscellaneous Commercial ServicesCommercial Services Dymedex Consulting LLC provides market development consulting services. It specializes in market analysis, strategic consulting and corporate integration. The company was founded in 2007 by Joseph Galatowitsch and Ross Meisner and is headquartered in St. Paul, MN. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
VectivBio AG
![]() VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Corporate Officer/Principal | |
EDGEWISE THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal | |
Neogene Therapeutics, Inc.
![]() Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Biotechnology | Director/Board Member | |
Capstan Therapeutics, Inc.
![]() Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Director/Board Member | |
iTeos Therapeutics SA
![]() iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Founder | |
VV Manager LLC
![]() VV Manager LLC Investment ManagersFinance VV Manager LLC (Vida Ventures) is a venture capital firm founded in 2017 by Arie Belldegrun, Arjun Goyal and Stefan Vitorovic. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
Therachon SAS
![]() Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Biotechnology | Founder | |
Iteos Belgium SA
![]() Iteos Belgium SA Pharmaceuticals: MajorHealth Technology Part of iTeos Therapeutics, Inc., iTeos Belgium SA is a Belgian company that manufactures pharmaceutical raw materials. The company is based in Gosselies, Belgium. The company was founded by Benoît van den Eynde. | Pharmaceuticals: Major | Chief Executive Officer | |
Ludwig Cancer Research | Director/Board Member | ||
Ona Therapeutics SL
![]() Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Pharmaceuticals: Major | Chairman | |
ITEOS THERAPEUTICS, INC. | Biotechnology | Founder | |
Ogeda SA
![]() Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Pharmaceuticals: Major | Director/Board Member | |
Weill Cornell Medicine | College/University | Doctorate Degree |
Statistics
International
United States | 10 |
Belgium | 5 |
Switzerland | 3 |
United Kingdom | 2 |
France | 2 |
Sectoral
Health Technology | 11 |
Consumer Services | 4 |
Commercial Services | 3 |
Technology Services | 2 |
Finance | 2 |
Operational
Director/Board Member | 11 |
Chief Executive Officer | 4 |
Founder | 4 |
Corporate Officer/Principal | 4 |
President | 3 |
Most connected contacts
Insiders | |
---|---|
Michel Detheux | 8 |
Behrad Derakhshan | 8 |
Rajul Jain | 5 |
Elvire Gouze | 2 |
- Stock Market
- Insiders
- Rachel Maers
- Company connections